



Supplementary Figure 3

a



b



Supplementary Figure 3. MGCD0103 decreases MAP1LC3-I levels in primary CLL cells at least partly through cleavage of ATG4B. **(a)** Scheme describing the actions of ATG4B. ATG4B processes proMAP1LC3 to MAP1LC3-I through cleavage of its C-terminal amino acid. MAP1LC3-I is then conjugated to PE by ATG3 and ATG7 (not shown) to form MAP1LC3-II. The ATG5-ATG12 complex stimulates LC3 lipidation. After autolysosome formation, ATG4B recycles MAP1LC3-II by catalyzing its delipidation. **(b)** PBMC from CLL patients were incubated with or without MGCD0103 (3 μ mol/L) in the absence or in the presence of Q-VD-OPh (Q-VD) (10 mmol/L) for 24 h and 48 h. Q-VD was added to PBMC 1 hour before MGCD0103. Representative blots from three independent experiments are shown. The levels of indicated proteins were analyzed by immunoblotting, using ACTB as a loading control.